1-13 of 13
Haiyi Guo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Hui-Peng Lee, Stephen S. Opat, John Hrom, David Kliman, Paula Marlton, Peng Liu, Chenmu Du, Amber Lussier, Jun Zhang, Haiyi Guo, Steven P. Treon
Journal: Blood
Blood (2024) 144 (Supplement 1): 1661.1.
https://doi.org/10.1182/blood-2024-198728
Published: 2024
Journal Articles

Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101

Jacob D. Soumerai, Chan Y. Cheah, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen S. Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Paolo Ghia, Sophie Leitch, David Westerman, Sheel Patel, Yiqian Fang, Wei Ding, Haiyi Guo, Constantine S. Tam
Journal: Blood
Blood (2024) 144 (Supplement 1): 1012.
https://doi.org/10.1182/blood-2024-199175
Published: 2024
Journal Articles

Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study

Constantine S. Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen S. Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Jacob Soumerai, Paolo Ghia, Sophie Leitch, James Hilger, Yiqian Fang, David Simpson, Haiyi Guo, Chan Yoon Cheah
Journal: Blood
Blood (2023) 142 (Supplement 1): 327.
https://doi.org/10.1182/blood-2023-179541
Published: 2023
Journal Articles

Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study

Alessandra Tedeschi, Chan Yoon Cheah, Stephen S. Opat, Emma Verner, Laura Magnano, Narendranath Epperla, James Hilger, Yiqian Fang, David Simpson, Haiyi Guo, Mary Ann Anderson
Journal: Blood
Blood (2023) 142 (Supplement 1): 3032.
https://doi.org/10.1182/blood-2023-178841
Published: 2023
Journal Articles

Efficacy and Safety of Zanubrutinib in Japanese Patients with Mature B-Cell Malignancies

Takayuki Ishikawa, Masahiro Takeuchi, Kazuyuki Shimada, Kohmei Kubo, Takeshi Kondo, Katsuya Fujimoto, Tomoaki Fujisaki, Koji Nagafuji, Rika Sakai, Shingo Kurahashi, Tatsuro Jo, Kazutaka Sunami, Senji Kasahara, Tomonori Nakazato, Haiyi Guo, William Novotny, Chris Tankersley, Motohisa Takai, Hui Yao, Jinhua Zhong, Hongjie Zhu, Koji Izutsu
Journal: Blood
Blood (2022) 140 (Supplement 1): 3663–3665.
https://doi.org/10.1182/blood-2022-168696
Published: 2022
Journal Articles

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Jake Shortt, Pau Montesinos, Shuh Ying Tan, Teng Fong Ng, Chun Yew Fong, Paul Cannell, Rajeev Rajagopal, Sophia Leitch, Peter T. Tan, Sundra Ramanathan, Robin Gasiorowski, Douglas Stuart Lenton, Tse-Chieh Teh, José Antonio Pérez-Simón, Carolyn Grove, Xiaojun Huang, Courtney D. DiNardo, Katherine Naidu, Joseph Pariseau, Si Cheng, Yu Liu, Melannie Co, Wai Y. Chan, Haiyi Guo, Andrew H. Wei
Journal: Blood
Blood (2022) 140 (Supplement 1): 3329–3332.
https://doi.org/10.1182/blood-2022-166937
Published: 2022
Journal Articles

Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Huilai Zhang, Keshu Zhou, Ying Cheng, Liling Zhang, Haiyan Yang, Liqun Zou, Junning Cao, Huiqiang Huang, Ye Guo, Zhao Wang, Sha Huang, Zhiyu Liang, Hui Yao, Haiyi Guo, Yiqian Fang, Hongjie Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 3750–3752.
https://doi.org/10.1182/blood-2022-155979
Published: 2022
Journal Articles

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Clinical Trials & Observations
Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Jane Huang, William Novotny, Pil Kim, Yiling Yu, Binghao Wu, Jun Zhu
Journal: Blood
Blood (2022) 139 (21): 3148–3158.
https://doi.org/10.1182/blood.2021014162
Published: 2022
Includes: Supplemental data
Journal Articles

Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action

Yuqin Song, MD PhD, Quanli Gao, MD, Lei Fan, MD PhD, Dehui Zou, MD, Huilai Zhang, MD PhD, Jianfeng Zhou, MD PhD, Wei Li, MD, Haiyan Yang, MD PhD, Ting Liu, MD PhD, Quanshun Wang, MD PhD, Fangfang Lv, MD, Dan Wang, PhD, Pei Zhang, PhD, Tengfei Liu, PhD, Yun Zhang, PhD, Zhirong Shen, PhD, Lei Wang, PhD, Liudi Yang, MD, Haiyi Guo, MD, Jun Zhu, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17.
https://doi.org/10.1182/blood-2020-136696
Published: 2020
Journal Articles

Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with WaldenstrC6m Macroglobulinemia from a Phase 2 Trial

Gang An, MD PhD, Daobin Zhou, MD PhD, Weili Zhao, MD PhD, Keshu Zhou, MD PhD, Jianyong Li, MD PhD, Jianfeng Zhou, MD PhD, Liping Xie, MD PhD, Jie Jin, MD PhD, Liye Zhong, MD PhD, Lingzhi Yan, MD PhD, Haiyi Guo, MD, Chenmu Du, MD, Jane Huang, MD, William Novotny, MD, Jinhua Zhong, PhD, Lugui Qiu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-136783
Published: 2020
Journal Articles

Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study

Yuqin Song, MD PhD, Quanli Gao, MD, Huilai Zhang, PhD, Lei Fan, MD PhD, Jianfeng Zhou, PhD, Dehui Zou, MD, Wei Li, MD, Haiyan Yang, PhD, Ting Liu, MD, Quanshun Wang, MD PhD, Fangfang Lv, MD, Yu Yang, MD, Haiyi Guo, MD, Liudi Yang, MD, Rebecca Elstrom, MD, Jane Huang, MD, William Novotny, MD, Vivian Wei, PhD, Jun Zhu, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 682.
https://doi.org/10.1182/blood-2018-99-117848
Published: 2018
Journal Articles

Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial

Yuqin Song, MD PhD, Keshu Zhou, MD, Dehui Zou, MD, Jianfeng Zhou, PhD, Jianda Hu, PhD, Haiyan Yang, PhD, Huilai Zhang, PhD, Jie Ji, MD, Wei Xu, MD PhD, Jie Jin, MD PhD, Fangfang Lv, MD, Ru Feng, MD, Sujun Gao, PhD, Daobin Zhou, MD, Haiyi Guo, MD, Aihua Wang, PhD, James Hilger, PhD, Jane Huang, MD, William Novotny, MD, Muhtar Osman, PhD, Jun Zhu, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 148.
https://doi.org/10.1182/blood-2018-99-117956
Published: 2018
Journal Articles

Effect of Eltrombopag on Platelet Response and Safety Results in Chinese Adults with Chronic ITP-Primary Result of a Phase III Study

Renchi Yang, MD, Ming Hou, MD, Junmin Li, MD PhD, Jie Jin, MD, Meijuan Huang, MD, Ziqiang Yu, MD, Xiaojun Xu, Xiaohui Zhang, Xin Du, MD, Ting Niu, MD PhD, Xiaoyan Ke, MD PhD, Jianmin Wang, MD PhD, Jing Liu, MD, Jing Sun, MD, Yongqiang Zhao, MD& PhD, Hua Lu, MD, Haiyi Guo, MD, Belinda Hsu, Senior statistician
Journal: Blood
Blood (2014) 124 (21): 1464.
https://doi.org/10.1182/blood.V124.21.1464.1464
Published: 2014